Skip to Main Content

View Public Comments for Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer (CAG-00422N)

Anonymous, Anonymous

There is major trial design flaw in trials.FDA/CMS need to investigate further before anyreimbursement. Placebo patients receivedsignificantly less tcells than Provenge armpatients (pbo only received 1/3 cells back). Thisdifference could have led to effect, but becauseof harm in pbo arm.

Full analysis here:

Provenge Analysis

Apologies for anon. Very sorry for patients andappreciate there is very vocal support, which hasbecome very threatening to some researcherstherefore staying anon. Even if this is redacted,do examine the trial design analysis to see themassive flaw.